Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome.
Journal
The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
10
2022
revised:
30
05
2023
accepted:
14
06
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy. We recruited 150 patients who received first-line palbociclib with hormonal therapy. 86% of patients developed 1st cycle neutropenia which was more common in patients with high Ki67. Dose reduction was recorded in 46.7% of patients and it was more common in patients with higher Allred scores (scores 7-8). The median progression-free survival (PFS) of the study group was 22 months. No significant difference was observed in PFS according to the 1st cycle of neutropenia or grade of neutropenia. Similarly, no difference in PFS according to palbociclib dose reduction and HER2 low status was observed. Only the Allred score and having a single site of metastasis had an independent significant relation with PFS. The median overall survival (OS) of the study group was 39 months. No significant difference was observed in OS according to the 1st cycle neutropenia, grade of neutropenia, palbociclib dose reduction, and HER2-low status. Only the Allred score and having a single site of metastasis had an independent significant relation with OS. In addition, no difference was observed in PFS and OS according to ECOG PS (2 vs. 0-1) or menopausal status. No significant impact of the 1st cycle neutropenia, dose reduction, having ECOG PS2, menopausal status, or HER2 low status on survival outcome was observed. Survival outcome was significantly better in patients with single metastatic sites and higher ER-Allred scores.
Sections du résumé
Background
CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy.
Results
We recruited 150 patients who received first-line palbociclib with hormonal therapy. 86% of patients developed 1st cycle neutropenia which was more common in patients with high Ki67. Dose reduction was recorded in 46.7% of patients and it was more common in patients with higher Allred scores (scores 7-8). The median progression-free survival (PFS) of the study group was 22 months. No significant difference was observed in PFS according to the 1st cycle of neutropenia or grade of neutropenia. Similarly, no difference in PFS according to palbociclib dose reduction and HER2 low status was observed. Only the Allred score and having a single site of metastasis had an independent significant relation with PFS. The median overall survival (OS) of the study group was 39 months. No significant difference was observed in OS according to the 1st cycle neutropenia, grade of neutropenia, palbociclib dose reduction, and HER2-low status. Only the Allred score and having a single site of metastasis had an independent significant relation with OS. In addition, no difference was observed in PFS and OS according to ECOG PS (2 vs. 0-1) or menopausal status.
Conclusion
No significant impact of the 1st cycle neutropenia, dose reduction, having ECOG PS2, menopausal status, or HER2 low status on survival outcome was observed. Survival outcome was significantly better in patients with single metastatic sites and higher ER-Allred scores.
Identifiants
pubmed: 37664544
doi: 10.1155/2023/8994954
pmc: PMC10473893
doi:
Substances chimiques
palbociclib
G9ZF61LE7G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8994954Informations de copyright
Copyright © 2023 Khaled Abd Elaziz Ahmed Elnaghi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
JAMA Netw Open. 2020 Oct 1;3(10):e2020312
pubmed: 33048129
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
Clin Cancer Res. 2007 Apr 1;13(7):1950-4
pubmed: 17404074
Breast Cancer Res. 2021 Dec 14;23(1):112
pubmed: 34906198
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Int J Mol Sci. 2020 Sep 04;21(18):
pubmed: 32899866
Medicine (Baltimore). 2018 May;97(20):e10746
pubmed: 29768351
Breast. 2021 Dec;60:263-271
pubmed: 34808438
Front Endocrinol (Lausanne). 2022 Aug 18;13:1000704
pubmed: 36060981
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Clin Cancer Res. 2014 Jul 1;20(13):3379-83
pubmed: 24795392
NPJ Breast Cancer. 2022 Jul 11;8(1):80
pubmed: 35817765
Breast Cancer Res. 2016 Jun 28;18(1):67
pubmed: 27349747
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Breast Cancer Res. 2018 May 2;20(1):37
pubmed: 29720233